Ali Razaghi
Ali Razaghi
Postdoctoral Researcher (PhD) at Karolinska Institute
Verified email at - Homepage
Cited by
Cited by
Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation
A Razaghi, L Owens, K Heimann
Journal of biotechnology 240, 48-60, 2016
Selenium stimulates the antitumour immunity: Insights to future research
A Razaghi, M Poorebrahim, D Sarhan, M Björnstedt
European Journal of Cancer 155, 256-267, 2021
Effects of nitrogen on growth and carbohydrate formation in Porphyridium cruentum
A Razaghi, A Godhe, E Albers
Open Life Sciences 9 (2), 156-162, 2014
Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies
A Razaghi, K Heimann, PM Schaeffer, SB Gibson
Apoptosis 23, 93-112, 2018
Hydrolysis treatments of fruit and vegetable waste for production of biofuel precursors
A Razaghi, OP Karthikeyan, HTN Hao, K Heimann
Bioresource Technology 217, 100-103, 2016
Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma?
A Razaghi, E Tan, LHL Lua, L Owens, OP Karthikeyan, K Heimann
Biologicals 45, 52-60, 2017
Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells
A Razaghi, C Villacrés, V Jung, N Mashkour, M Butler, L Owens, ...
Experimental cell research 359 (1), 20-29, 2017
Culture scale-up and immobilisation of a mixed methanotrophic consortium for methane remediation in pilot-scale bio-filters
OP Karthikeyan, N Saravanan, S Cirés, C Alvarez-Roa, A Razaghi, ...
Environmental technology 38 (4), 474-482, 2017
Recycling of food waste for fuel precursors using an integrated bio-refinery approach
OP Karthikeyan, HTN Hao, A Razaghi, K Heimann
Bioresource technology 248, 194-198, 2018
Characterization of Xanthomonas citri subsp. malvacearum strains in Iran
A Razaghi, N Hasanzadeh, A Ghasemi
African Journal of Microbiology Research 6 (6), 1165-1170, 2012
Copy number alteration of the interferon gene cluster in cancer: Individual patient data meta-analysis prospects to personalized immunotherapy
A Razaghi, N Brusselaers, M Björnstedt, M Durand-Dubief
Neoplasia 23 (10), 1059-1068, 2021
Soluble PD-L1 expression after intravenous treatment of cancer patients with selenite in phase I clinical trial
A Razaghi, L Mansouri, O Brodin, M Björnstedt, J Lundahl
Frontiers in oncology 12, 906134, 2022
Selenofolate inhibits the proliferation of IGROV1 cancer cells independently from folate receptor alpha
A Razaghi, AM Zickler, J Spallholz, G Kirsch, M Björnstedt
Heliyon 7 (6), 2021
Proteomic analysis of pleural effusions from COVID-19 deceased patients: Enhanced inflammatory markers
A Razaghi, A Szakos, M Alouda, B Bozóky, M Björnstedt, L Szekely
Diagnostics 12 (11), 2789, 2022
Increased expression and secretion of recombinant hIFNγ through amino acid starvation-induced selective pressure on the adjacent HIS4 gene in Pichia pastoris
A Razaghi, R Huerlimann, L Owens, K Heimann
European Pharmaceutical Journal 62 (2), 43-50, 2015
Morphological changes without histological myocarditis in hearts of COVID-19 deceased patients
A Razaghi, A Szakos, R Al-Shakarji, M Björnstedt, L Szekely
Scandinavian Cardiovascular Journal 56 (1), 166-173, 2022
Methods for accurate and reproducible studies of pharmacological effects of selenium in cancer
AK Selvam, T Szekerczés, S Björnstedt, A Razaghi, M Björnstedt
Methods in Enzymology 662, 25-62, 2022
Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites
O Breuer, O Brodin, A Razaghi, D Brodin, B Gammelgaard, M Björnstedt
Biomedicines 11 (2), 295, 2023
Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy
A Razaghi, M Durand-Dubief, N Brusselaers, M Björnstedt
Frontiers in Immunology 14, 2023
The system can't perform the operation now. Try again later.
Articles 1–19